Biogen delays 'complex and unpredecented' Alzheimer’s drug application By: Boston Business Journal via Business Journals April 22, 2020 at 10:20 AM EDT Biogen previously said it expected to ask the FDA to approve its Alzheimer's drug aducanumab in “early 2020”. Read More >>